Daré Bioscience Completes Second Closing of Regulation A Offering

Daré Bioscience ( (DARE) ) has issued an announcement.

On March 6, 2026, Daré Bioscience completed the second closing of its previously announced Regulation A offering of Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants. In this closing, the company issued 17,500 Investor Units, comprising 17,500 shares of Series A Preferred Stock and warrants to purchase up to 35,000 shares of common stock, providing additional capital that may support ongoing operations and strategic initiatives while modestly diluting existing equity holders.

The offering is being conducted under an offering statement on Form 1-A that was qualified by the U.S. Securities and Exchange Commission on January 5, 2026, with an accompanying offering circular dated January 6, 2026. This second closing marks continued investor participation in Daré’s capital-raising efforts, reinforcing access to financing in a competitive biopharmaceutical funding environment and potentially strengthening the company’s financial position for development activities.

The most recent analyst rating on (DARE) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Spark’s Take on DARE Stock

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

The score is held down primarily by weak financial performance (minimal/declining revenue, ongoing losses, and TTM cash burn) and only modest technical strength (below key moving averages). These are partially offset by a relatively positive earnings call focused on upcoming product launches and a grant-supported pipeline, plus supportive financing and strategic control developments from recent corporate events.

To see Spark’s full report on DARE stock, click here.

More about Daré Bioscience

Daré Bioscience, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing products in the women’s health space. Its activities center on advancing clinical-stage candidates and technologies intended to address unmet needs in reproductive and gynecologic health, targeting both U.S. and global markets through a capital-intensive R&D and regulatory pathway.

Average Trading Volume: 156,673

Technical Sentiment Signal: Strong Sell

Current Market Cap: $21.86M

See more data about DARE stock on TipRanks’ Stock Analysis page.